华海药业：达格列净二甲双胍缓释片获药品注册证书

Core Viewpoint - Huahai Pharmaceutical (600521) has received the drug registration certificate for Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, which is intended for improving blood glucose control in adult patients with type 2 diabetes currently treated with Dapagliflozin and Metformin [1] Summary by Categories Product Development - The company has invested approximately 18.31 million yuan in the research and development of this project [1] Market Position - The approval of the drug registration certificate enhances the company's product line, contributing to improved market competitiveness [1] Business Impact - This development is expected to have a positive effect on the company's operational growth [1]